Business
Rockwell Medical, Inc. Appoints John P. McLaughlin Chairman of the Board of Directors
WIXOM, Mich., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company
About this update from Rockwell Medical, Inc.
[{"type":"text","content":"WIXOM, Mich., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to improving outcomes for patients with anemia, with an initial focus on end-stage renal disease (ESRD), today announced the appointment of John P. McLaughlin as its Chairman of the Board, effective immediately. Mr. McLaughlin, who joined the Board on September 5, 2019, succeeds Benjamin Wolin, who will remain on the Board of Directors.\n “This is a truly pivotal time for Rockwell Medical with the recent commercial launch of Dialysate Triferic® (ferric pyrophosphate citrate) and the filing for approval of I.V. Triferic. I am honored to serve as Chairman of the Board of Directors and look forward to working with the rest of Rockwell Medical’s talented Board and management team as the Company works to transform anemia management in a variety of disease states around the globe and establish Triferic as the standard of care for anemia management in ESRD patients. We are grateful to Ben for his service as Chairman, and we are excited that he will remain an active member of the Board,” said John P. McLaughlin, Chairman of the Board. Mr. McLaughlin currently also serves on the Board of PDL BioPharma, Inc. where he was Chief Executive Officer for 10 years; Noden Pharma DAC, a Dublin-based pharma company that commercializes hypertension drugs worldwide; and Lensar Inc., a medical technology company that commercializes lasers for refractive cataract surgery worldwide. He has previously co-founded and sold, as well as served on the boards of, a number of biotechnology and medical technology companies. About Triferic Triferic is the only FDA-approved therapy indicated to replace iron and maintain hemoglobin in hemodialysis patients via dialysate during each dialysis treatment. Triferic delivers approximately 5-7 mg iron with every hemodialysis treatment to the bone marrow and maintains hemoglobin without increasing iron stores (ferritin). Unlike traditional IV iron products, Triferic donates iron immediately and completely to transferrin (carrier of iron in the body) upon entry into the blood and is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no reports of anaphylaxis in over 1,000,...